Skip to main content

Table 3 Frequency of adverse events reported in dogs randomized to receive either fluralaner flavored chewable tablets or spinosad together with amitraz

From: A randomized, blinded, controlled USA field study to assess the use of fluralaner tablets in controlling canine flea infestations

Adverse Event Fluralaner, dogs observed over 26 weeks Spinosad + Amitraz, dogs observed over 12 weeks
(N = 224) (N = 70)
Emesis 16 (7.1%) 10 (14.3%)
Decreased appetite 15 (6.7%) 0 (0.0%)
Diarrhea 11 (4.9%) 2 (2.9%)
Lethargy 12 (5.4%) 5 (7.1%)
Polydipsia 4 (1.8%) 3 (4.3%)
Flatulence 3 (1.3%) 0 (0.0%)